The incidence of Klebsiella pneumoniae (K. pneumoniae) infection in patients with cirrhosis has been increasing over recent years, posing certain difficulties in clinical treatment.

To analyze the clinical features of patients with liver cirrhosis and identify the risk factors to help the early diagnosis and treatment of these diseases.

Clinical data and laboratory tests were collected from 72 patients with cirrhosis confirmed by secretion or blood culture of K. pneumoniae infection at Beijing Ditan Hospital, Capital Medical University, between May 2016 and October 2018. Data from hospitalized patients with liver cirrhosis and K. pneumoniae infections, including age, sex, antimicrobial use, length of stay, site of infection, distribution of pathogenic bacteria, complications, invasive operations, laboratory indicators, treatment, and clinical regression, were extracted and retrospectively analyzed. Clinical data and biochemical values were included in the multivariate logistic regression analysis.

A total of 52 men and 20 women, with an age range from 29 to 85 years and an average age of 57.7 ± 12.54, were analyzed. The incidence of hospital K. pneumoniae infection in patients with cirrhosis was approximately 19.44%. The most common the infection site was the bloodstream, followed by the respiratory tract, abdominal cavity, and biliary tract. Risk factors for infection were old age, long hospital stays, gastrointestinal bleeding, and low serum albumin levels, while prophylactic antibiotics were protective factors. The multivariate analysis suggested that other infections, chronic diseases, and invasive procedures were independent factors.

In clinical practice, the length of hospital stays should be shortened as much as possible, invasive operations should be reduced, antibiotics should be rationally used, and the patients’ liver function should be timely improved. This is of great significance for reducing the incidence of hospital infection.

• Klebsiella pneumoniae
• Cirrhosis
• Antibiotics
• Logistic regression
• Hospital infection

• Albumin
• Ascites
• Cirrhosis

• Albumins/administration & dosage
• Ascites/complications
• Ascites/drug therapy
• Ascites/mortality
• Humans
• Liver Cirrhosis/complications
• Liver Cirrhosis/drug therapy
• Liver Cirrhosis/mortality
• Randomized Controlled Trials as Topic
• Recurrence
• Risk
• Secondary Prevention
• Time Factors
• Treatment Outcome

• Ascites
• Cirrhosis
• Hepatorenal syndrome
• Portal Hypertension
• Spontaneous bacterial peritonitis
• refractory ascites;